Sign In
Buy IMMX
$8.32
-0.230 (-2.69%)
At Close: Jul 31, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX
10:00am, Thursday, 30'th Jul 2026
NEW YORK, July 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Immix Biopharma, Inc. ("Immix" or the "Company") (NASDAQ: IMMX). Such investors are advised to
IMMX INVESTIGATION: Securities Fraud Investigation by Block & Leviton Could Allow Immix Biopharma Investors to Recover Losses
08:15am, Thursday, 23'rd Jul 2026
Boston, Massachusetts--(Newsfile Corp. - July 23, 2026) - Block & Leviton is investigating Immix Biopharma (NASDAQ: IMMX) for potential securities law violations. Investors who have lost money in thei
Immix Biopharma Investigated by the Portnoy Law Firm
01:51pm, Tuesday, 21'st Jul 2026
LOS ANGELES, July 21, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Immix Biopharma , (“ Immix " or the "Company") ( NASDAQ : IMMX ) investors that the firm has initiated an investigation in
IMMX INVESTOR ALERT: Holzer & Holzer, LLC Announces Investigation of Immix Biopharma, Inc.
05:33pm, Monday, 20'th Jul 2026
ATLANTA, July 20, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Immix Biopharma, Inc. (“Immix” or the “Company”) (NASDAQ: IMMX) complied with federal securities laws.
Philadelphia, Pennsylvania--(Newsfile Corp. - July 20, 2026) - Kehoe Law Firm, P.C. is investigating potential securities fraud claims on behalf of investors of Immix Biopharma, Inc. ("Immix Biopharma
IMMX ALERT: Immix Biopharma Investigated for Securities Fraud Violations by Block & Leviton; Investors Should Contact the Firm
11:47am, Monday, 20'th Jul 2026
BOSTON, July 20, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Immix Biopharma (Nasdaq: IMMX) for potential securities law violations. Investors who have lost money in their Immix Biopharm
All You Need to Know About Immix Biopharma (IMMX) Rating Upgrade to Buy
01:01pm, Wednesday, 24'th Jun 2026
Immix Biopharma (IMMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Immix Biopharma Analyst Bullish But Flags Safety, Adoption Questions
01:38pm, Thursday, 18'th Jun 2026
BofA Securities initiates Immix Biopharma with Buy rating, citing NXC-201's potential in AL amyloidosis and peak sales near $963 million.
Wall Street Analysts Think Immix Biopharma (IMMX) Could Surge 113.58%: Read This Before Placing a Bet
10:55am, Thursday, 18'th Jun 2026
The consensus price target hints at an 113.6% upside potential for Immix Biopharma (IMMX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings
Wall Street Analysts See a 120.59% Upside in Immix Biopharma (IMMX): Can the Stock Really Move This High?
10:55am, Wednesday, 27'th May 2026
The consensus price target hints at a 120.6% upside potential for Immix Biopharma (IMMX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings
Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock
05:15pm, Friday, 22'nd May 2026
– Financing includes leading U.S. biotechnology institutional investors and mutual funds – LOS ANGELES, CA, May 22, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, �
Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock
06:30am, Thursday, 21'st May 2026
LOS ANGELES, May 21, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a global leader in AL Amyloidosis, today announced the pricing
Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2
06:00am, Thursday, 21'st May 2026
– Of first 20 patients, all four MRD-negative patients have converted to complete response (CR) – – CR rate now 95% (19 of 20 patients) – – All CRs reached within 1 yea
Immix Biopharma to Participate in the Jefferies Global Healthcare Conference
08:45am, Thursday, 09'th Apr 2026
LOS ANGELES, CA, April 09, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis,
Brokerages Set Immix Biopharma, Inc. (NASDAQ:IMMX) Price Target at $18.25
01:09am, Monday, 06'th Apr 2026
Shares of Immix Biopharma, Inc. (NASDAQ: IMMX - Get Free Report) have been given an average rating of "Moderate Buy" by the six ratings firms that are covering the company, MarketBeat.com reports. One
